Quarterly ResultJul 23, 2026, 04:13 PM
Summit Therapeutics Q2 Net Loss $215.7M; Going Concern Doubt
AI Summary
Summit Therapeutics reported a net loss of $215.7 million for the second quarter of 2026 and $405.1 million for the first six months. The company explicitly stated that its current cash and short-term investments are not sufficient to fund operations for at least one year, raising substantial doubt about its ability to continue as a going concern. Summit raised $227.4 million through an at-the-market offering and received an upfront payment of $0.5 million from the sale of its ridinilazole asset.
Key Highlights
- Net loss for Q2 2026 was $215.7 million, with a six-month net loss of $405.1 million.
- Cash and cash equivalents totaled $419.4 million as of June 30, 2026.
- Cash used in operating activities for the six months ended June 30, 2026, was $263.4 million.
- Company's cash and investments are insufficient to fund operations for one year, raising going concern doubt.
- Raised $227.4 million from an at-the-market (ATM) offering during the six-month period.
- Sold ridinilazole asset for an upfront payment of $0.5 million, with potential future milestones.
- Research and development expenses decreased to $157.7 million in Q2 2026 from $208.0 million in Q2 2025.
- Accumulated deficit reached $2.7 billion as of June 30, 2026.
Price Impact
More from SMMT